<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33804386</PMID><DateCompleted><Year>2021</Year><Month>11</Month><Day>19</Day></DateCompleted><DateRevised><Year>2021</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2073-4409</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>3</Issue><PubDate><Year>2021</Year><Month>Mar</Month><Day>01</Day></PubDate></JournalIssue><Title>Cells</Title><ISOAbbreviation>Cells</ISOAbbreviation></Journal><ArticleTitle>Tumor Necrosis Factor Alpha in Amyotrophic Lateral Sclerosis: Friend or Foe?</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">518</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/cells10030518</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterized by a massive neuroinflammatory reaction, which plays a key role in the progression of the disease. One of the major mediators of the inflammatory response is the pleiotropic cytokine tumor necrosis factor &#x3b1; (TNF&#x3b1;), mainly released within the central nervous system (CNS) by reactive astrocytes and microglia. Increased levels of TNF&#x3b1; and its receptors (TNFR1 and TNFR2) have been described in plasma, serum, cerebrospinal fluid and CNS tissue from both ALS patients and transgenic animal models of disease. However, the precise role exerted by TNF&#x3b1; in the context of ALS is still highly controversial, since both protective and detrimental functions have been reported. These opposing actions depend on multiple factors, among which includes the type of TNF&#x3b1; receptor activated. In fact, TNFR2 seems to mediate a harmful role being involved in motor neuron cell death, whereas TNFR1 signaling mediates neuroprotective effects, promoting the expression and secretion of trophic factors. This suggests that a better understanding of the cytokine impact on ALS progression may enable the development of effective therapies aimed at strengthening the protective roles of TNF&#x3b1; and at suppressing the detrimental ones.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Guidotti</LastName><ForeName>Giulia</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Laboratory for Research on Neurodegenerative Disorders, Istituti Clinici Scientifici Maugeri IRCCS, 27100 Pavia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scarlata</LastName><ForeName>Chiara</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Laboratory for Research on Neurodegenerative Disorders, Istituti Clinici Scientifici Maugeri IRCCS, 27100 Pavia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brambilla</LastName><ForeName>Liliana</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Laboratory for Research on Neurodegenerative Disorders, Istituti Clinici Scientifici Maugeri IRCCS, 27100 Pavia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rossi</LastName><ForeName>Daniela</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-3346-1327</Identifier><AffiliationInfo><Affiliation>Laboratory for Research on Neurodegenerative Disorders, Istituti Clinici Scientifici Maugeri IRCCS, 27100 Pavia, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>03</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Cells</MedlineTA><NlmUniqueID>101600052</NlmUniqueID><ISSNLinking>2073-4409</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014409" MajorTopicYN="N">Tumor Necrosis Factor-alpha</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">motor neuron degeneration</Keyword><Keyword MajorTopicYN="N">neuroinflammation</Keyword><Keyword MajorTopicYN="N">rehabilitation</Keyword><Keyword MajorTopicYN="N">tumor necrosis factor alpha</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>12</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>2</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>2</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>4</Month><Day>3</Day><Hour>1</Hour><Minute>17</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>4</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>11</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33804386</ArticleId><ArticleId IdType="pmc">PMC8000008</ArticleId><ArticleId IdType="doi">10.3390/cells10030518</ArticleId><ArticleId IdType="pii">cells10030518</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Brown R.H., Al-Chalabi A. Amyotrophic Lateral Sclerosis. N. Engl. J. Med. 2017;377:162&#x2013;172. doi: 10.1056/NEJMra1603471.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra1603471</ArticleId><ArticleId IdType="pubmed">28700839</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossi D. Astrocyte physiopathology: At the crossroads of intercellular networking, inflammation and cell death. Prog. Neurobiol. 2015;130:86&#x2013;120. doi: 10.1016/j.pneurobio.2015.04.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pneurobio.2015.04.003</ArticleId><ArticleId IdType="pubmed">25930681</ArticleId></ArticleIdList></Reference><Reference><Citation>Valori C.F., Guidotti G., Brambilla L., Rossi D. Astrocytes in Motor Neuron Diseases. Adv. Exp. Med. Biol. 2019;1175:227&#x2013;272. doi: 10.1007/978-981-13-9913-8_10.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-981-13-9913-8_10</ArticleId><ArticleId IdType="pubmed">31583591</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardiman O., Al-Chalabi A., Chio A., Corr E.M., Logroscino G., Robberecht W., Shaw P.J., Simmons Z., Berg L.H.V.D. Amyotrophic lateral sclerosis. Nat. Rev. Dis. Prim. 2017;3:nrdp201771-17071. doi: 10.1038/nrdp.2017.71.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrdp.2017.71</ArticleId><ArticleId IdType="pubmed">28980624</ArticleId></ArticleIdList></Reference><Reference><Citation>A van Es M., Hardiman O., Chio A., Al-Chalabi A., Pasterkamp R.J., Veldink J.H., Berg L.H.V.D. Amyotrophic lateral sclerosis. Lancet. 2017;390:2084&#x2013;2098. doi: 10.1016/S0140-6736(17)31287-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(17)31287-4</ArticleId><ArticleId IdType="pubmed">28552366</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy J., Factor-Litvak P., Goetz R.R., Lomen-Hoerth C., Nagy P.L., Hupf J., Singleton J., Woolley S., Andrews J.A., Heitzman D., et al. Cognitive-behavioral screening reveals prevalent impairment in a large multicenter ALS cohort. Neurology. 2016;86:813&#x2013;820. doi: 10.1212/WNL.0000000000002305.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000002305</ArticleId><ArticleId IdType="pmc">PMC4793785</ArticleId><ArticleId IdType="pubmed">26802094</ArticleId></ArticleIdList></Reference><Reference><Citation>Trojsi F., Siciliano M., Femiano C., Santangelo G., Lunetta C., Calvo A., Moglia C., Marinou K., Ticozzi N., Ferrante G.D., et al. Comorbidity of dementia with amyotrophic lateral sclerosis (ALS): Insights from a large multicenter Italian cohort. J. Neurol. 2017;264:2224&#x2013;2231. doi: 10.1007/s00415-017-8619-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-017-8619-4</ArticleId><ArticleId IdType="pubmed">28914354</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsitkanou S., Della Gatta P., Foletta V., Russell A. The Role of Exercise as a Non-pharmacological Therapeutic Approach for Amyotrophic Lateral Sclerosis: Beneficial or Detrimental? Front. Neurol. 2019;10:783. doi: 10.3389/fneur.2019.00783.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2019.00783</ArticleId><ArticleId IdType="pmc">PMC6652799</ArticleId><ArticleId IdType="pubmed">31379732</ArticleId></ArticleIdList></Reference><Reference><Citation>Lunetta C., Lizio A., Sansone V.A., Cellotto N.M., Maestri E., Bettinelli M., Gatti V., Melazzini M.G., Meola G., Corbo M. Strictly monitored exercise programs reduce motor deterioration in ALS: Preliminary results of a randomized controlled trial. J. Neurol. 2016;263:52&#x2013;60. doi: 10.1007/s00415-015-7924-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-015-7924-z</ArticleId><ArticleId IdType="pubmed">26477027</ArticleId></ArticleIdList></Reference><Reference><Citation>Merico A., Cavinato M., Gregorio C., Lacatena A., Gioia E., Piccione F., Angelini C. Effects of combined endurance and resistance training in Amyotrophic Lateral Sclerosis: A pilot, randomized, controlled study. Eur. J. Transl. Myol. 2018;28:7278. doi: 10.4081/ejtm.2018.7278.</Citation><ArticleIdList><ArticleId IdType="doi">10.4081/ejtm.2018.7278</ArticleId><ArticleId IdType="pmc">PMC5895987</ArticleId><ArticleId IdType="pubmed">29686818</ArticleId></ArticleIdList></Reference><Reference><Citation>Jensen L., Djurtoft J.B., Bech R.D., Nielsen J.L., J&#xf8;rgensen L.H., Schr&#xf8;der H.D., Frandsen U., Aagaard P., Hvid L.G. Influence of Resistance Training on Neuromuscular Function and Physical Capacity in ALS Patients. J. Neurodegener. Dis. 2017;2017:1&#x2013;8. doi: 10.1155/2017/1436519.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2017/1436519</ArticleId><ArticleId IdType="pmc">PMC5449732</ArticleId><ArticleId IdType="pubmed">28596929</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang T., Al Khleifat A., Meurgey J.-H., Jones A., Leigh P.N., Bensimon G., Al-Chalabi A. Stage at which riluzole treatment prolongs survival in patients with amyotrophic lateral sclerosis: A retrospective analysis of data from a dose-ranging study. Lancet Neurol. 2018;17:416&#x2013;422. doi: 10.1016/S1474-4422(18)30054-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(18)30054-1</ArticleId><ArticleId IdType="pmc">PMC5899963</ArticleId><ArticleId IdType="pubmed">29525492</ArticleId></ArticleIdList></Reference><Reference><Citation>Abe K., Aoki M., Tsuji S., Itoyama Y., Sobue G., Togo M., Hamada C., Tanaka M., Akimoto M., Nakamura K., et al. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: A randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2017;16:505&#x2013;512. doi: 10.1016/S1474-4422(17)30115-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(17)30115-1</ArticleId><ArticleId IdType="pubmed">28522181</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Chalabi A., Hardiman O. The epidemiology of ALS: A conspiracy of genes, environment and time. Nat. Rev. Neurol. 2013;9:617&#x2013;628. doi: 10.1038/nrneurol.2013.203.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2013.203</ArticleId><ArticleId IdType="pubmed">24126629</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen D.R., Siddique T., Patterson D., Figlewicz D.A., Sapp P.C., Hentati A., Donaldson D.H., Goto J., O&#x2019;Regan J.P., Deng H.-X., et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature. 1993;362:59&#x2013;62. doi: 10.1038/362059a0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/362059a0</ArticleId><ArticleId IdType="pubmed">8446170</ArticleId></ArticleIdList></Reference><Reference><Citation>Gurney M.E., Pu H., Chiu A.Y., Dal Canto M.C., Polchow C.Y., Alexander D.D., Caliendo J., Hentati A., Kwon Y.W., Deng H.X., et al. Motor neuron degeneration in mice that express a human Cu, Zn superoxide dismutase mutation. Science. 1994;264:1772&#x2013;1775. doi: 10.1126/science.8209258.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.8209258</ArticleId><ArticleId IdType="pubmed">8209258</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner B.J., Talbot K. Transgenics, toxicity and therapeutics in rodent models of mutant SOD1-mediated familial ALS. Prog. Neurobiol. 2008;85:94&#x2013;134. doi: 10.1016/j.pneurobio.2008.01.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pneurobio.2008.01.001</ArticleId><ArticleId IdType="pubmed">18282652</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor J.P., Jr., Brown R.H., Cleveland D.W. Decoding ALS: From genes to mechanism. Nat. Cell Biol. 2016;539:197&#x2013;206. doi: 10.1038/nature20413.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature20413</ArticleId><ArticleId IdType="pmc">PMC5585017</ArticleId><ArticleId IdType="pubmed">27830784</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner M.R., Hardiman O., Benatar M., Brooks B.R., Chio A., De Carvalho M., Ince P.G., Lin C., Miller R.G., Mitsumoto H., et al. Controversies and priorities in amyotrophic lateral sclerosis. Lancet Neurol. 2013;12:310&#x2013;322. doi: 10.1016/S1474-4422(13)70036-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(13)70036-X</ArticleId><ArticleId IdType="pmc">PMC4565161</ArticleId><ArticleId IdType="pubmed">23415570</ArticleId></ArticleIdList></Reference><Reference><Citation>Pegoraro V., Merico A., Angelini C. Micro-RNAs in ALS muscle: Differences in gender, age at onset and disease duration. J. Neurol. Sci. 2017;380:58&#x2013;63. doi: 10.1016/j.jns.2017.07.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2017.07.008</ArticleId><ArticleId IdType="pmc">PMC5598142</ArticleId><ArticleId IdType="pubmed">28870590</ArticleId></ArticleIdList></Reference><Reference><Citation>Tasca E., Pegoraro V., Merico A., Angelini C. Circulating microRNAs as biomarkers of muscle differentiation and atrophy in ALS. Clin. Neuropathol. 2016;35:22&#x2013;30. doi: 10.5414/NP300889.</Citation><ArticleIdList><ArticleId IdType="doi">10.5414/NP300889</ArticleId><ArticleId IdType="pubmed">26588026</ArticleId></ArticleIdList></Reference><Reference><Citation>Pegoraro V., Marozzo R., Angelini C. MicroRNAs and HDAC4 protein expression in the skeletal muscle of ALS patients. Clin. Neuropathol. 2020;39:105&#x2013;114. doi: 10.5414/NP301233.</Citation><ArticleIdList><ArticleId IdType="doi">10.5414/NP301233</ArticleId><ArticleId IdType="pubmed">32000889</ArticleId></ArticleIdList></Reference><Reference><Citation>McGeer P.L., McGeer E.G. Inflammatory processes in amyotrophic lateral sclerosis. Muscle Nerve. 2002;26:459&#x2013;470. doi: 10.1002/mus.10191.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.10191</ArticleId><ArticleId IdType="pubmed">12362410</ArticleId></ArticleIdList></Reference><Reference><Citation>Clement A.M. Wild-Type Nonneuronal Cells Extend Survival of SOD1 Mutant Motor Neurons in ALS Mice. Science. 2003;302:113&#x2013;117. doi: 10.1126/science.1086071.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1086071</ArticleId><ArticleId IdType="pubmed">14526083</ArticleId></ArticleIdList></Reference><Reference><Citation>Boill&#xe9;e S., Yamanaka K., Lobsiger C.S., Copeland N.G., Jenkins N.A., Kassiotis G., Kollias G., Cleveland D.W. Onset and Progression in Inherited ALS Determined by Motor Neurons and Microglia. Science. 2006;312:1389&#x2013;1392. doi: 10.1126/science.1123511.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1123511</ArticleId><ArticleId IdType="pubmed">16741123</ArticleId></ArticleIdList></Reference><Reference><Citation>Valori C.F., Brambilla L., Martorana F., Rossi D. The multifaceted role of glial cells in amyotrophic lateral sclerosis. Cell. Mol. Life Sci. 2013;71:287&#x2013;297. doi: 10.1007/s00018-013-1429-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00018-013-1429-7</ArticleId><ArticleId IdType="pubmed">23912896</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghezzi P., Bernardini R., Giuffrida R., Bellomo M., Manzoni C., Comoletti D., Di Santo E., Benigni F., Mennini T. Tumor necrosis factor is increased in the spinal cord of an animal model of motor neuron degeneration. Eur. Cytokine Netw. 1998;9:139&#x2013;144.</Citation><ArticleIdList><ArticleId IdType="pubmed">9681389</ArticleId></ArticleIdList></Reference><Reference><Citation>Poloni M., Facchetti D., Mai R., Micheli A., Agnoletti L., Francolini G., Mora G., Camana C., Mazzini L., Bachetti T. Circulating levels of tumour necrosis factor-&#x3b1; and its soluble receptors are increased in the blood of patients with amyotrophic lateral sclerosis. Neurosci. Lett. 2000;287:211&#x2013;214. doi: 10.1016/S0304-3940(00)01177-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0304-3940(00)01177-0</ArticleId><ArticleId IdType="pubmed">10863032</ArticleId></ArticleIdList></Reference><Reference><Citation>Cereda C., Baiocchi C., Bongioanni P., Cova E., Guareschi S., Metelli M.R., Rossi B., Sbalsi I., Cuccia M.C., Ceroni M. TNF and sTNFR1/2 plasma levels in ALS patients. J. Neuroimmunol. 2008;194:123&#x2013;131. doi: 10.1016/j.jneuroim.2007.10.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jneuroim.2007.10.028</ArticleId><ArticleId IdType="pubmed">18083240</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreau C., Devos D., Brunaud-Danel V., Defebvre L., Perez T., Destee A., Tonnel A.B., Lassalle P., Just N. Elevated IL-6 and TNF- levels in patients with ALS: Inflammation or hypoxia? Neurology. 2005;65:1958&#x2013;1960. doi: 10.1212/01.wnl.0000188907.97339.76.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000188907.97339.76</ArticleId><ArticleId IdType="pubmed">16380619</ArticleId></ArticleIdList></Reference><Reference><Citation>Philips T., Robberecht W. Neuroinflammation in amyotrophic lateral sclerosis: Role of glial activation in motor neuron disease. Lancet Neurol. 2011;10:253&#x2013;263. doi: 10.1016/S1474-4422(11)70015-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(11)70015-1</ArticleId><ArticleId IdType="pubmed">21349440</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothstein J.D., Martin L.J., Kuncl R.W. Decreased Glutamate Transport by the Brain and Spinal Cord in Amyotrophic Lateral Sclerosis. N. Engl. J. Med. 1992;326:1464&#x2013;1468. doi: 10.1056/NEJM199205283262204.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM199205283262204</ArticleId><ArticleId IdType="pubmed">1349424</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruijn L.I., Becher M.W., Lee M.K., Anderson K.L., Jenkins N.A., Copeland N.G., Sisodia S.S., Rothstein J.D., Borchelt D.R., Price D.L., et al. ALS-Linked SOD1 Mutant G85R Mediates Damage to Astrocytes and Promotes Rapidly Progressive Disease with SOD1-Containing Inclusions. Neuron. 1997;18:327&#x2013;338. doi: 10.1016/S0896-6273(00)80272-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0896-6273(00)80272-X</ArticleId><ArticleId IdType="pubmed">9052802</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamanaka K., Chun S.J., Boillee S., Fujimori-Tonou N., Yamashita H., Gutmann D.H., Takahashi R., Misawa H., Cleveland D.W. Astrocytes as determinants of disease progression in inherited amyotrophic lateral sclerosis. Nat. Neurosci. 2008;11:251&#x2013;253. doi: 10.1038/nn2047.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn2047</ArticleId><ArticleId IdType="pmc">PMC3137510</ArticleId><ArticleId IdType="pubmed">18246065</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L., Gutmann D.H., Roos R.P. Astrocyte loss of mutant SOD1 delays ALS disease onset and progression in G85R transgenic mice. Hum. Mol. Genet. 2010;20:286&#x2013;293. doi: 10.1093/hmg/ddq463.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddq463</ArticleId><ArticleId IdType="pubmed">20962037</ArticleId></ArticleIdList></Reference><Reference><Citation>Papadeas S.T., Kraig S.E., O&#x2019;Banion C., Lepore A.C., Maragakis N.J. Astrocytes carrying the superoxide dismutase 1 (SOD1G93A) mutation induce wild-type motor neuron degeneration in vivo. Proc. Natl. Acad. Sci. USA. 2011;108:17803&#x2013;17808. doi: 10.1073/pnas.1103141108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1103141108</ArticleId><ArticleId IdType="pmc">PMC3203804</ArticleId><ArticleId IdType="pubmed">21969586</ArticleId></ArticleIdList></Reference><Reference><Citation>Kondo T., Funayama M., Tsukita K., Hotta A., Yasuda A., Nori S., Kaneko S., Nakamura M., Takahashi R., Okano H., et al. Focal Transplantation of Human iPSC-Derived Glial-Rich Neural Progenitors Improves Lifespan of ALS Mice. Stem Cell Rep. 2014;3:242&#x2013;249. doi: 10.1016/j.stemcr.2014.05.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stemcr.2014.05.017</ArticleId><ArticleId IdType="pmc">PMC4175543</ArticleId><ArticleId IdType="pubmed">25254338</ArticleId></ArticleIdList></Reference><Reference><Citation>Lepore A.C., Rauck B., Dejea C., Pardo A.C., Rao M.S., Rothstein J.D., Maragakis N.J. Focal transplantation&#x2013;based astrocyte replacement is neuroprotective in a model of motor neuron disease. Nat. Neurosci. 2008;11:1294&#x2013;1301. doi: 10.1038/nn.2210.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.2210</ArticleId><ArticleId IdType="pmc">PMC2656686</ArticleId><ArticleId IdType="pubmed">18931666</ArticleId></ArticleIdList></Reference><Reference><Citation>Qian K., Huang H., Peterson A., Hu B., Maragakis N.J., Ming G.-L., Chen H., Zhang S.-C. Sporadic ALS Astrocytes Induce Neuronal Degeneration In Vivo. Stem Cell Rep. 2017;8:843&#x2013;855. doi: 10.1016/j.stemcr.2017.03.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stemcr.2017.03.003</ArticleId><ArticleId IdType="pmc">PMC5390239</ArticleId><ArticleId IdType="pubmed">28366455</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawamata T., Akiyama H., Yamada T., McGeer P.L. Immunologic reactions in amyotrophic lateral sclerosis brain and spinal cord tissue. Am. J. Pathol. 1992;140:691&#x2013;707.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1886170</ArticleId><ArticleId IdType="pubmed">1347673</ArticleId></ArticleIdList></Reference><Reference><Citation>Engelhardt J.I., Tajti J., Appel S.H. Lymphocytic Infiltrates in the Spinal Cord in Amyotrophic Lateral Sclerosis. Arch. Neurol. 1993;50:30&#x2013;36. doi: 10.1001/archneur.1993.00540010026013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.1993.00540010026013</ArticleId><ArticleId IdType="pubmed">8093428</ArticleId></ArticleIdList></Reference><Reference><Citation>Henkel J.S., Engelhardt J.I., Sikl&#xf3;s L., Simpson E.P., Kim S.H., Pan T., Goodman J.C., Siddique T., Beers D.R., Appel S.H. Presence of dendritic cells, MCP-1, and activated microglia/macrophages in amyotrophic lateral sclerosis spinal cord tissue. Ann. Neurol. 2003;55:221&#x2013;235. doi: 10.1002/ana.10805.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.10805</ArticleId><ArticleId IdType="pubmed">14755726</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagy D., Kato T., Kushner P.D. Reactive astrocytes are widespread in the cortical gray matter of amyotrophic lateral sclerosis. J. Neurosci. Res. 1994;38:336&#x2013;347. doi: 10.1002/jnr.490380312.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jnr.490380312</ArticleId><ArticleId IdType="pubmed">7523689</ArticleId></ArticleIdList></Reference><Reference><Citation>Kushner P.D., Stephenson D.T., Wright S. Reactive Astrogliosis is Widespread in the Subcortical White Matter of Amyotrophic Lateral Sclerosis Brain. J. Neuropathol. Exp. Neurol. 1991;50:263&#x2013;277. doi: 10.1097/00005072-199105000-00008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00005072-199105000-00008</ArticleId><ArticleId IdType="pubmed">2022968</ArticleId></ArticleIdList></Reference><Reference><Citation>Schiffer D., Cordera S., Cavalla P., Migheli A. Reactive astrogliosis of the spinal cord in amyotrophic lateral sclerosis. J. Neurol. Sci. 1996;139:27&#x2013;33. doi: 10.1016/0022-510X(96)00073-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0022-510X(96)00073-1</ArticleId><ArticleId IdType="pubmed">8899654</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner M.R., Cagnin A., Turkheimer F.E., Miller C.C.J., Shaw C.E., Brooks D.J., Leigh P.N., Banati R.B. Evidence of widespread cerebral microglial activation in amyotrophic lateral sclerosis: An [11C](R)-PK11195 positron emission tomography study. Neurobiol. Dis. 2004;15:601&#x2013;609. doi: 10.1016/j.nbd.2003.12.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2003.12.012</ArticleId><ArticleId IdType="pubmed">15056468</ArticleId></ArticleIdList></Reference><Reference><Citation>Corcia P., Tauber C., Vercoullie J., Arlicot N., Prunier C., Praline J., Nicolas G., Venel Y., Hommet C., Baulieu J.-L., et al. Molecular Imaging of Microglial Activation in Amyotrophic Lateral Sclerosis. PLoS ONE. 2012;7:e52941. doi: 10.1371/journal.pone.0052941.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0052941</ArticleId><ArticleId IdType="pmc">PMC3534121</ArticleId><ArticleId IdType="pubmed">23300829</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexianu M.E., Kozovska M., Appel S.H. Immune reactivity in a mouse model of familial ALS correlates with disease progression. Neurology. 2001;57:1282&#x2013;1289. doi: 10.1212/WNL.57.7.1282.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.57.7.1282</ArticleId><ArticleId IdType="pubmed">11591849</ArticleId></ArticleIdList></Reference><Reference><Citation>Saxena S., Cabuy E., Caroni P. A role for motoneuron subtype&#x2013;selective ER stress in disease manifestations of FALS mice. Nat. Neurosci. 2009;12:627&#x2013;636. doi: 10.1038/nn.2297.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.2297</ArticleId><ArticleId IdType="pubmed">19330001</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanagi T., Yuasa S., Nakamura Y., Suzuki E., Aoki M., Warita H., Itoyama Y., Uchino S., Kohsaka S., Ohsawa K. Appearance of phagocytic microglia adjacent to motoneurons in spinal cord tissue from a presymptomatic transgenic rat model of amyotrophic lateral sclerosis. J. Neurosci. Res. 2010;88:2736&#x2013;2746. doi: 10.1002/jnr.22424.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jnr.22424</ArticleId><ArticleId IdType="pubmed">20648658</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerber Y.N., Sabourin J.-C., R&#xe1;bano M., Vivanco M.D.M., Perrin F.E. Early Functional Deficit and Microglial Disturbances in a Mouse Model of Amyotrophic Lateral Sclerosis. PLoS ONE. 2012;7:e36000. doi: 10.1371/journal.pone.0036000.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0036000</ArticleId><ArticleId IdType="pmc">PMC3338492</ArticleId><ArticleId IdType="pubmed">22558300</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossi D., Brambilla L., Valori C.F., Roncoroni C., Crugnola A., Yokota T., Bredesen D.E., Volterra A. Focal degeneration of astrocytes in amyotrophic lateral sclerosis. Cell Death Differ. 2008;15:1691&#x2013;1700. doi: 10.1038/cdd.2008.99.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cdd.2008.99</ArticleId><ArticleId IdType="pubmed">18617894</ArticleId></ArticleIdList></Reference><Reference><Citation>Beers D.R., Zhao W., Liao B., Kano O., Wang J., Huang A., Appel S.H., Henkel J.S. Neuroinflammation modulates distinct regional and temporal clinical responses in ALS mice. Brain Behav. Immun. 2011;25:1025&#x2013;1035. doi: 10.1016/j.bbi.2010.12.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2010.12.008</ArticleId><ArticleId IdType="pmc">PMC3096756</ArticleId><ArticleId IdType="pubmed">21176785</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao W., Beers D.R., Appel S.H. Immune-mediated Mechanisms in the Pathoprogression of Amyotrophic Lateral Sclerosis. J. Neuroimmune Pharmacol. 2013;8:888&#x2013;899. doi: 10.1007/s11481-013-9489-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11481-013-9489-x</ArticleId><ArticleId IdType="pmc">PMC4126425</ArticleId><ArticleId IdType="pubmed">23881705</ArticleId></ArticleIdList></Reference><Reference><Citation>Beers D.R., Henkel J.S., Zhao W., Wang J., Appel S.H. CD4+ T cells support glial neuroprotection, slow disease progression, and modify glial morphology in an animal model of inherited ALS. Proc. Natl. Acad. Sci. USA. 2008;105:15558&#x2013;15563. doi: 10.1073/pnas.0807419105.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0807419105</ArticleId><ArticleId IdType="pmc">PMC2547419</ArticleId><ArticleId IdType="pubmed">18809917</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiu I.M., Chen A., Zheng Y., Kosaras B., Tsiftsoglou S.A., Vartanian T.K., Brown R.H., Carroll M.C. T lymphocytes potentiate endogenous neuroprotective inflammation in a mouse model of ALS. Proc. Natl. Acad. Sci. USA. 2008;105:17913&#x2013;17918. doi: 10.1073/pnas.0804610105.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0804610105</ArticleId><ArticleId IdType="pmc">PMC2581614</ArticleId><ArticleId IdType="pubmed">18997009</ArticleId></ArticleIdList></Reference><Reference><Citation>Henkel J.S., Beers D.R., Wen S., Rivera A.L., Toennis K.M., Appel J.E., Zhao W., Moore D.H., Powell S.Z., Appel S.H. Regulatory T-lymphocytes mediate amyotrophic lateral sclerosis progression and survival. EMBO Mol. Med. 2012;5:64&#x2013;79. doi: 10.1002/emmm.201201544.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/emmm.201201544</ArticleId><ArticleId IdType="pmc">PMC3569654</ArticleId><ArticleId IdType="pubmed">23143995</ArticleId></ArticleIdList></Reference><Reference><Citation>Beers D.R., Zhao W., Wang J., Zhang X., Wen S., Neal D., Thonhoff J.R., Alsuliman A.S., Shpall E.J., Rezvani K., et al. ALS patients&#x2019; regulatory T lymphocytes are dysfunctional, and correlate with disease progression rate and severity. JCI Insight. 2017;2:e89530. doi: 10.1172/jci.insight.89530.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.89530</ArticleId><ArticleId IdType="pmc">PMC5333967</ArticleId><ArticleId IdType="pubmed">28289705</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen X., Oppenheim J.J. Contrasting effects of TNF and anti-TNF on the activation of effector T cells and regulatory T cells in autoimmunity. FEBS Lett. 2011;585:3611&#x2013;3618. doi: 10.1016/j.febslet.2011.04.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.febslet.2011.04.025</ArticleId><ArticleId IdType="pmc">PMC3164898</ArticleId><ArticleId IdType="pubmed">21513711</ArticleId></ArticleIdList></Reference><Reference><Citation>Valencia X., Stephens G., Goldbach-Mansky R., Wilson M., Shevach E.M., Lipsky P.E. TNF downmodulates the function of human CD4+CD25hi T-regulatory cells. Blood. 2006;108:253&#x2013;261. doi: 10.1182/blood-2005-11-4567.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2005-11-4567</ArticleId><ArticleId IdType="pmc">PMC1895836</ArticleId><ArticleId IdType="pubmed">16537805</ArticleId></ArticleIdList></Reference><Reference><Citation>Pehar M., Harlan B.A., Killoy K.M., Vargas M.R. Role and Therapeutic Potential of Astrocytes in Amyotrophic Lateral Sclerosis. Curr. Pharm. Des. 2018;23:5010&#x2013;5021. doi: 10.2174/1381612823666170622095802.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1381612823666170622095802</ArticleId><ArticleId IdType="pmc">PMC5740017</ArticleId><ArticleId IdType="pubmed">28641533</ArticleId></ArticleIdList></Reference><Reference><Citation>Brambilla L., Guidotti G., Martorana F., Iyer A.M., Aronica E., Valori C.F., Rossi D. Disruption of the astrocytic TNFR1-GDNF axis accelerates motor neuron degeneration and disease progression in amyotrophic lateral sclerosis. Hum. Mol. Genet. 2016;25:3080&#x2013;3095. doi: 10.1093/hmg/ddw161.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddw161</ArticleId><ArticleId IdType="pubmed">27288458</ArticleId></ArticleIdList></Reference><Reference><Citation>Endo F., Komine O., Fujimori-Tonou N., Katsuno M., Jin S., Watanabe S., Sobue G., Dezawa M., Wyss-Coray T., Yamanaka K. Astrocyte-Derived TGF-&#x3b2;1 Accelerates Disease Progression in ALS Mice by Interfering with the Neuroprotective Functions of Microglia and T Cells. Cell Rep. 2015;11:592&#x2013;604. doi: 10.1016/j.celrep.2015.03.053.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2015.03.053</ArticleId><ArticleId IdType="pubmed">25892237</ArticleId></ArticleIdList></Reference><Reference><Citation>Endo F., Yamanaka K. Astrocytic TGF-&#x3b2;1: Detrimental factor in ALS. Oncotarget. 2015;6:15728&#x2013;15729. doi: 10.18632/oncotarget.4786.</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/oncotarget.4786</ArticleId><ArticleId IdType="pmc">PMC4599223</ArticleId><ArticleId IdType="pubmed">26164079</ArticleId></ArticleIdList></Reference><Reference><Citation>Hensley K. Message and protein-level elevation of tumor necrosis factor &#x3b1; (TNF&#x3b1;) and TNF&#x3b1;-modulating cytokines in spinal cords of the G93A-SOD1 mouse model for amyotrophic lateral sclerosis. Neurobiol. Dis. 2003;14:74&#x2013;80. doi: 10.1016/S0969-9961(03)00087-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0969-9961(03)00087-1</ArticleId><ArticleId IdType="pubmed">13678668</ArticleId></ArticleIdList></Reference><Reference><Citation>Hooten K.G., Beers D.R., Zhao W., Appel S.H. Protective and Toxic Neuroinflammation in Amyotrophic Lateral Sclerosis. Neurotherapeutics. 2015;12:364&#x2013;375. doi: 10.1007/s13311-014-0329-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13311-014-0329-3</ArticleId><ArticleId IdType="pmc">PMC4404435</ArticleId><ArticleId IdType="pubmed">25567201</ArticleId></ArticleIdList></Reference><Reference><Citation>Keiner S., Wurm F., Kunze A., Witte O.W., Redecker C. Rehabilitative therapies differentially alter proliferation and survival of glial cell populations in the perilesional zone of cortical infarcts. Glia. 2008;56:516&#x2013;527. doi: 10.1002/glia.20632.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/glia.20632</ArticleId><ArticleId IdType="pubmed">18240310</ArticleId></ArticleIdList></Reference><Reference><Citation>Latimer C.S., Searcy J.L., Bridges M.T., Brewer L.D., Popovic J., Blalock E.M., Landfield P.W., Thibault O., Porter N.M. Reversal of Glial and Neurovascular Markers of Unhealthy Brain Aging by Exercise in Middle-Aged Female Mice. PLoS ONE. 2011;6:e26812. doi: 10.1371/journal.pone.0026812.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0026812</ArticleId><ArticleId IdType="pmc">PMC3201977</ArticleId><ArticleId IdType="pubmed">22046366</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodr&#xed;guez J.J., Terzieva S., Olabarria M., Lanza R.G., Verkhratsky A. Enriched environment and physical activity reverse astrogliodegeneration in the hippocampus of AD transgenic mice. Cell Death Dis. 2013;4:e678. doi: 10.1038/cddis.2013.194.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cddis.2013.194</ArticleId><ArticleId IdType="pmc">PMC3702309</ArticleId><ArticleId IdType="pubmed">23788035</ArticleId></ArticleIdList></Reference><Reference><Citation>Saur L., Baptista P.P.A., De Senna P.N., Paim M.F., Nascimento P.D., Ilha J., Bagatini P.B., Achaval M., Xavier L.L. Physical exercise increases GFAP expression and induces morphological changes in hippocampal astrocytes. Brain Struct. Funct. 2014;219:293&#x2013;302. doi: 10.1007/s00429-012-0500-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00429-012-0500-8</ArticleId><ArticleId IdType="pubmed">23288255</ArticleId></ArticleIdList></Reference><Reference><Citation>Mee-Inta O., Zhao Z.-W., Kuo Y.-M. Physical Exercise Inhibits Inflammation and Microglial Activation. Cells. 2019;8:691. doi: 10.3390/cells8070691.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells8070691</ArticleId><ArticleId IdType="pmc">PMC6678635</ArticleId><ArticleId IdType="pubmed">31324021</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernardes D., Oliveira-Lima O.C., Da Silva T.V., Faraco C.C.F., Leite H.R., Juliano M.A., Dos Santos D.M., Bethea J.R., Brambilla R., Orian J.M., et al. Differential brain and spinal cord cytokine and BDNF levels in experimental autoimmune encephalomyelitis are modulated by prior and regular exercise. J. Neuroimmunol. 2013;264:24&#x2013;34. doi: 10.1016/j.jneuroim.2013.08.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jneuroim.2013.08.014</ArticleId><ArticleId IdType="pubmed">24054000</ArticleId></ArticleIdList></Reference><Reference><Citation>Leem Y.-H., Lee Y.-I., Son H.-J., Lee S.-H. Chronic exercise ameliorates the neuroinflammation in mice carrying NSE/htau23. Biochem. Biophys. Res. Commun. 2011;406:359&#x2013;365. doi: 10.1016/j.bbrc.2011.02.046.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2011.02.046</ArticleId><ArticleId IdType="pubmed">21329662</ArticleId></ArticleIdList></Reference><Reference><Citation>Piao C.-S., Stoica B.A., Wu J., Sabirzhanov B., Zhao Z., Cabatbat R., Loane D.J., Faden A.I. Late exercise reduces neuroinflammation and cognitive dysfunction after traumatic brain injury. Neurobiol. Dis. 2013;54:252&#x2013;263. doi: 10.1016/j.nbd.2012.12.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2012.12.017</ArticleId><ArticleId IdType="pmc">PMC3628975</ArticleId><ArticleId IdType="pubmed">23313314</ArticleId></ArticleIdList></Reference><Reference><Citation>McCoy M.K., Tansey M.G. TNF signaling inhibition in the CNS: Implications for normal brain function and neurodegenerative disease. J. Neuroinflam. 2008;5:45. doi: 10.1186/1742-2094-5-45.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1742-2094-5-45</ArticleId><ArticleId IdType="pmc">PMC2577641</ArticleId><ArticleId IdType="pubmed">18925972</ArticleId></ArticleIdList></Reference><Reference><Citation>Cabal-Hierro L., Lazo P.S. Signal transduction by tumor necrosis factor receptors. Cell. Signal. 2012;24:1297&#x2013;1305. doi: 10.1016/j.cellsig.2012.02.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cellsig.2012.02.006</ArticleId><ArticleId IdType="pubmed">22374304</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohler K.M., Torrance D.S., A Smith C., Goodwin R.G., E Stremler K., Fung V.P., Madani H., Widmer M.B. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J. Immunol. 1993;151:1548&#x2013;1561.</Citation><ArticleIdList><ArticleId IdType="pubmed">8393046</ArticleId></ArticleIdList></Reference><Reference><Citation>Aderka D., Engelmann H., Maor Y., Brakebusch C., Wallach D. Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors. J. Exp. Med. 1992;175:323&#x2013;329. doi: 10.1084/jem.175.2.323.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.175.2.323</ArticleId><ArticleId IdType="pmc">PMC2119112</ArticleId><ArticleId IdType="pubmed">1310100</ArticleId></ArticleIdList></Reference><Reference><Citation>Baud V., Karin M. Signal transduction by tumor necrosis factor and its relatives. Trends Cell Biol. 2001;11:372&#x2013;377. doi: 10.1016/S0962-8924(01)02064-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0962-8924(01)02064-5</ArticleId><ArticleId IdType="pubmed">11514191</ArticleId></ArticleIdList></Reference><Reference><Citation>Sedger L.M., McDermott M.F. TNF and TNF-receptors: From mediators of cell death and inflammation to therapeutic giants&#x2013;past, present and future. Cytokine Growth Factor Rev. 2014;25:453&#x2013;472. doi: 10.1016/j.cytogfr.2014.07.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cytogfr.2014.07.016</ArticleId><ArticleId IdType="pubmed">25169849</ArticleId></ArticleIdList></Reference><Reference><Citation>Pekalski J., Zuk P.J., Kocha&#x144;czyk M., Junkin M., Kellogg R., Tay S., Lipniacki T. Spontaneous NF-&#x3ba;B Activation by Autocrine TNF&#x3b1; Signaling: A Computational Analysis. PLoS ONE. 2013;8:e78887. doi: 10.1371/journal.pone.0078887.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0078887</ArticleId><ArticleId IdType="pmc">PMC3855823</ArticleId><ArticleId IdType="pubmed">24324544</ArticleId></ArticleIdList></Reference><Reference><Citation>Haidet-Phillips A.M., Hester M.E., Miranda C.J., Meyer K., Braun L., Frakes A., Song S., Likhite S., Murtha M.J., Foust K.D., et al. Astrocytes from familial and sporadic ALS patients are toxic to motor neurons. Nat. Biotechnol. 2011;29:824&#x2013;828. doi: 10.1038/nbt.1957.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt.1957</ArticleId><ArticleId IdType="pmc">PMC3170425</ArticleId><ArticleId IdType="pubmed">21832997</ArticleId></ArticleIdList></Reference><Reference><Citation>Swarup V., Phaneuf D., Dupr&#xe9; N., Petri S., Strong M., Kriz J., Julien J.-P. Deregulation of TDP-43 in amyotrophic lateral sclerosis triggers nuclear factor &#x3ba;B&#x2013;mediated pathogenic pathways. J. Exp. Med. 2011;208:2429&#x2013;2447. doi: 10.1084/jem.20111313.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20111313</ArticleId><ArticleId IdType="pmc">PMC3256969</ArticleId><ArticleId IdType="pubmed">22084410</ArticleId></ArticleIdList></Reference><Reference><Citation>Frakes A.E., Ferraiuolo L., Haidet-Phillips A.M., Schmelzer L., Braun L., Miranda C.J., Ladner K.J., Bevan A.K., Foust K.D., Godbout J.P., et al. Microglia Induce Motor Neuron Death via the Classical NF-&#x3ba;B Pathway in Amyotrophic Lateral Sclerosis. Neuron. 2014;81:1009&#x2013;1023. doi: 10.1016/j.neuron.2014.01.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2014.01.013</ArticleId><ArticleId IdType="pmc">PMC3978641</ArticleId><ArticleId IdType="pubmed">24607225</ArticleId></ArticleIdList></Reference><Reference><Citation>Crosio C., Valle C., Casciati A., Iaccarino C., Carr&#xec; M.T. Astroglial Inhibition of NF-&#x3ba;B Does Not Ameliorate Disease Onset and Progression in a Mouse Model for Amyotrophic Lateral Sclerosis (ALS) PLoS ONE. 2011;6:e17187. doi: 10.1371/journal.pone.0017187.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0017187</ArticleId><ArticleId IdType="pmc">PMC3060799</ArticleId><ArticleId IdType="pubmed">21445241</ArticleId></ArticleIdList></Reference><Reference><Citation>Alami N.O., Schurr C., Heuvel F.O., Tang L., Li Q., Tasdogan A., Kimbara A., Nettekoven M., Ottaviani G., Raposo C., et al. NF-&#x3ba;B activation in astrocytes drives a stage-specific beneficial neuroimmunological response in ALS. EMBO J. 2018;37 doi: 10.15252/embj.201798697.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embj.201798697</ArticleId><ArticleId IdType="pmc">PMC6092622</ArticleId><ArticleId IdType="pubmed">29875132</ArticleId></ArticleIdList></Reference><Reference><Citation>Afonso V., Santos G., Collin P., Khatib A.-M., Mitrovic D.R., Lomri N., Leitman D.C., Lomri A. Tumor necrosis factor-&#x3b1; down-regulates human Cu/Zn superoxide dismutase 1 promoter via JNK/AP-1 signaling pathway. Free. Radic. Biol. Med. 2006;41:709&#x2013;721. doi: 10.1016/j.freeradbiomed.2006.05.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.freeradbiomed.2006.05.014</ArticleId><ArticleId IdType="pubmed">16895791</ArticleId></ArticleIdList></Reference><Reference><Citation>Semmler S., Gagn&#xe9; M., Garg P., Pickles S.R., Baudouin C., Hamon-Keromen E., Destroismaisons L., Khalfallah Y., Chaineau M., Caron E., et al. TNF receptor&#x2013;associated factor 6 interacts with ALS-linked misfolded superoxide dismutase 1 and promotes aggregation. J. Biol. Chem. 2020;295:3808&#x2013;3825. doi: 10.1074/jbc.RA119.011215.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.RA119.011215</ArticleId><ArticleId IdType="pmc">PMC7086032</ArticleId><ArticleId IdType="pubmed">32029478</ArticleId></ArticleIdList></Reference><Reference><Citation>Vitkovic L., Bockaert J., Jacque C. &#x201c;Inflammatory&#x201d; Cytokines. J. Neurochem. 2001;74:457&#x2013;471. doi: 10.1046/j.1471-4159.2000.740457.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1471-4159.2000.740457.x</ArticleId><ArticleId IdType="pubmed">10646496</ArticleId></ArticleIdList></Reference><Reference><Citation>Cearley C., Churchill L., Krueger J.M. Time of day differences in IL1&#x3b2; and TNF&#x3b1; mRNA levels in specific regions of the rat brain. Neurosci. Lett. 2003;352:61&#x2013;63. doi: 10.1016/j.neulet.2003.07.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2003.07.019</ArticleId><ArticleId IdType="pubmed">14615050</ArticleId></ArticleIdList></Reference><Reference><Citation>Iosif R.E., Ekdahl C.T., Ahlenius H., Pronk C.J.H., Bonde S., Kokaia Z., Jacobsen S.-E.W., Lindvall O. Tumor Necrosis Factor Receptor 1 Is a Negative Regulator of Progenitor Proliferation in Adult Hippocampal Neurogenesis. J. Neurosci. 2006;26:9703&#x2013;9712. doi: 10.1523/JNEUROSCI.2723-06.2006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2723-06.2006</ArticleId><ArticleId IdType="pmc">PMC6674454</ArticleId><ArticleId IdType="pubmed">16988041</ArticleId></ArticleIdList></Reference><Reference><Citation>Wheeler M.A., Heffner D.L., Kim S., Espy S.M., Spano A.J., Cleland C.L., Deppmann C.D. TNF-&#x3b1;/TNFR1 Signaling Is Required for the Development and Function of Primary Nociceptors. Neuron. 2014;82:587&#x2013;602. doi: 10.1016/j.neuron.2014.04.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2014.04.009</ArticleId><ArticleId IdType="pmc">PMC4046273</ArticleId><ArticleId IdType="pubmed">24811380</ArticleId></ArticleIdList></Reference><Reference><Citation>Santello M., Volterra A. TNF&#x3b1; in synaptic function: Switching gears. Trends Neurosci. 2012;35:638&#x2013;647. doi: 10.1016/j.tins.2012.06.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tins.2012.06.001</ArticleId><ArticleId IdType="pubmed">22749718</ArticleId></ArticleIdList></Reference><Reference><Citation>Beattie E.C., Stellwagen D., Morishita W., Bresnahan J.C., Ha B.K., Von Zastrow M., Beattie M.S., Malenka R.C. Control of Synaptic Strength by Glial TNFalpha. Science. 2002;295:2282&#x2013;2285. doi: 10.1126/science.1067859.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1067859</ArticleId><ArticleId IdType="pubmed">11910117</ArticleId></ArticleIdList></Reference><Reference><Citation>Stellwagen D., Beattie E.C., Seo J.Y., Malenka R.C. Differential Regulation of AMPA Receptor and GABA Receptor Trafficking by Tumor Necrosis Factor. J. Neurosci. 2005;25:3219&#x2013;3228. doi: 10.1523/JNEUROSCI.4486-04.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.4486-04.2005</ArticleId><ArticleId IdType="pmc">PMC6725093</ArticleId><ArticleId IdType="pubmed">15788779</ArticleId></ArticleIdList></Reference><Reference><Citation>Stellwagen D., Malenka R.C. Synaptic scaling mediated by glial TNF-&#x3b1;. Nat. Cell Biol. 2006;440:1054&#x2013;1059. doi: 10.1038/nature04671.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature04671</ArticleId><ArticleId IdType="pubmed">16547515</ArticleId></ArticleIdList></Reference><Reference><Citation>Santello M., Bezzi P., Volterra A. TNF&#x3b1; Controls Glutamatergic Gliotransmission in the Hippocampal Dentate Gyrus. Neuron. 2011;69:988&#x2013;1001. doi: 10.1016/j.neuron.2011.02.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2011.02.003</ArticleId><ArticleId IdType="pubmed">21382557</ArticleId></ArticleIdList></Reference><Reference><Citation>Taoufik E., Petit E., Divoux D., Tseveleki V., Mengozzi M., Roberts M.L., Valable S., Ghezzi P., Quackenbush J., Brines M., et al. TNF receptor I sensitizes neurons to erythropoietin- and VEGF-mediated neuroprotection after ischemic and excitotoxic injury. Proc. Natl. Acad. Sci. USA. 2008;105:6185&#x2013;6190. doi: 10.1073/pnas.0801447105.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0801447105</ArticleId><ArticleId IdType="pmc">PMC2299225</ArticleId><ArticleId IdType="pubmed">18413601</ArticleId></ArticleIdList></Reference><Reference><Citation>Ngo S., Steyn F., Huang L., Mantovani S., Pfluger C., Woodruff T.M., Osullivan J.D., Henderson R., A McCombe P. Altered expression of metabolic proteins and adipokines in patients with amyotrophic lateral sclerosis. J. Neurol. Sci. 2015;357:22&#x2013;27. doi: 10.1016/j.jns.2015.06.053.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2015.06.053</ArticleId><ArticleId IdType="pubmed">26198021</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu C.-H., Allen K., Oei F., Leoni E., Kuhle J., Tree T., Fratta P., Sharma N., Sidle K., Howard R., et al. Systemic inflammatory response and neuromuscular involvement in amyotrophic lateral sclerosis. Neurol.-Neuroimmunol. Neuroinflamm. 2016;3:e244. doi: 10.1212/NXI.0000000000000244.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/NXI.0000000000000244</ArticleId><ArticleId IdType="pmc">PMC4897985</ArticleId><ArticleId IdType="pubmed">27308305</ArticleId></ArticleIdList></Reference><Reference><Citation>Tateishi T., Yamasaki R., Tanaka M., Matsushita T., Kikuchi H., Isobe N., Ohyagi Y., Kira J.-I. CSF chemokine alterations related to the clinical course of amyotrophic lateral sclerosis. J. Neuroimmunol. 2010;222:76&#x2013;81. doi: 10.1016/j.jneuroim.2010.03.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jneuroim.2010.03.004</ArticleId><ArticleId IdType="pubmed">20381883</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen X., Hu Y., Cao Z., Liu Q., Cheng Y. Cerebrospinal Fluid Inflammatory Cytokine Aberrations in Alzheimer&#x2019;s Disease, Parkinson&#x2019;s Disease and Amyotrophic Lateral Sclerosis: A Systematic Review and Meta-Analysis. Front. Immunol. 2018;9:2122. doi: 10.3389/fimmu.2018.02122.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2018.02122</ArticleId><ArticleId IdType="pmc">PMC6156158</ArticleId><ArticleId IdType="pubmed">30283455</ArticleId></ArticleIdList></Reference><Reference><Citation>Babu G.N., Kumar A., Chandra R., Puri S.K., Kalita J., Misra U.K. Elevated Inflammatory Markers in a Group of Amyotrophic Lateral Sclerosis Patients from Northern India. Neurochem. Res. 2008;33:1145&#x2013;1149. doi: 10.1007/s11064-007-9564-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11064-007-9564-x</ArticleId><ArticleId IdType="pubmed">18246426</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukazawa H., Tsukie T., Higashida K., Fujikura M., Ono S. An immunohistochemical study of increased tumor necrosis factor-&#x3b1; in the skin of patients with amyotrophic lateral sclerosis. J. Clin. Neurosci. 2013;20:1371&#x2013;1376. doi: 10.1016/j.jocn.2012.11.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jocn.2012.11.007</ArticleId><ArticleId IdType="pubmed">23850047</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiaei M., Petri S., Kipiani K., Gardian G., Choi D.-K., Chen J., Calingasan N.Y., Schafer P., Muller G.W., Stewart C., et al. Thalidomide and Lenalidomide Extend Survival in a Transgenic Mouse Model of Amyotrophic Lateral Sclerosis. J. Neurosci. 2006;26:2467&#x2013;2473. doi: 10.1523/JNEUROSCI.5253-05.2006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.5253-05.2006</ArticleId><ArticleId IdType="pmc">PMC6793668</ArticleId><ArticleId IdType="pubmed">16510725</ArticleId></ArticleIdList></Reference><Reference><Citation>Brohawn D.G., O&#x2019;Brien L.C., Bennett J.P. RNAseq Analyses Identify Tumor Necrosis Factor-Mediated Inflammation as a Major Abnormality in ALS Spinal Cord. PLoS ONE. 2016;11:e0160520. doi: 10.1371/journal.pone.0160520.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0160520</ArticleId><ArticleId IdType="pmc">PMC4972368</ArticleId><ArticleId IdType="pubmed">27487029</ArticleId></ArticleIdList></Reference><Reference><Citation>Hensley K., Floyd R.A., Gordon B., Mou S., Pye Q.N., Stewart C., West M., Williamson K. Temporal patterns of cytokine and apoptosis-related gene expression in spinal cords of the G93A-SOD1 mouse model of amyotrophic lateral sclerosis. J. Neurochem. 2002;82:365&#x2013;374. doi: 10.1046/j.1471-4159.2002.00968.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1471-4159.2002.00968.x</ArticleId><ArticleId IdType="pubmed">12124437</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshihara T., Ishigaki S., Yamamoto M., Liang Y., Niwa J.-I., Takeuchi H., Doyu M., Sobue G. Differential expression of inflammation- and apoptosis-related genes in spinal cords of a mutant SOD1 transgenic mouse model of familial amyotrophic lateral sclerosis. J. Neurochem. 2002;80:158&#x2013;167. doi: 10.1046/j.0022-3042.2001.00683.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.0022-3042.2001.00683.x</ArticleId><ArticleId IdType="pubmed">11796754</ArticleId></ArticleIdList></Reference><Reference><Citation>Veglianese P., Coco D.L., Cutrona M.B., Magnoni R., Pennacchini D., Pozzi B., Gowing G., Julien J., Tortarolo M., Bendotti C. Activation of the p38MAPK cascade is associated with upregulation of TNF alpha receptors in the spinal motor neurons of mouse models of familial ALS. Mol. Cell. Neurosci. 2006;31:218&#x2013;231. doi: 10.1016/j.mcn.2005.09.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mcn.2005.09.009</ArticleId><ArticleId IdType="pubmed">16219474</ArticleId></ArticleIdList></Reference><Reference><Citation>Tolosa L., Caraballo-Miralles V., Olmos G., Llado J. TNF-&#x3b1; potentiates glutamate-induced spinal cord motoneuron death via NF-&#x3ba;B. Mol. Cell. Neurosci. 2011;46:176&#x2013;186. doi: 10.1016/j.mcn.2010.09.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mcn.2010.09.001</ArticleId><ArticleId IdType="pubmed">20849956</ArticleId></ArticleIdList></Reference><Reference><Citation>Winkler E.A., Sengillo J.D., Sullivan J.S., Henkel J.S., Appel S.H., Zlokovic B.V. Blood&#x2013;spinal cord barrier breakdown and pericyte reductions in amyotrophic lateral sclerosis. Acta Neuropathol. 2012;125:111&#x2013;120. doi: 10.1007/s00401-012-1039-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-012-1039-8</ArticleId><ArticleId IdType="pmc">PMC3535352</ArticleId><ArticleId IdType="pubmed">22941226</ArticleId></ArticleIdList></Reference><Reference><Citation>Zlokovic B.V. Neurovascular pathways to neurodegeneration in Alzheimer&#x2019;s disease and other disorders. Nat. Rev. Neurosci. 2011;12:723&#x2013;738. doi: 10.1038/nrn3114.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn3114</ArticleId><ArticleId IdType="pmc">PMC4036520</ArticleId><ArticleId IdType="pubmed">22048062</ArticleId></ArticleIdList></Reference><Reference><Citation>Winkler E.A., Sengillo J.D., Sagare A.P., Zhao Z., Ma Q., Zuniga E., Wang Y., Zhong Z., Sullivan J.S., Griffin J.H., et al. Blood-spinal cord barrier disruption contributes to early motor-neuron degeneration in ALS-model mice. Proc. Natl. Acad. Sci. USA. 2014;111:E1035&#x2013;E1042. doi: 10.1073/pnas.1401595111.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1401595111</ArticleId><ArticleId IdType="pmc">PMC3964055</ArticleId><ArticleId IdType="pubmed">24591593</ArticleId></ArticleIdList></Reference><Reference><Citation>Jablonski M.R., Jacob D.A., Campos C., Miller D.S., Maragakis N.J., Pasinelli P., Trotti D. Selective increase of two ABC drug efflux transporters at the blood&#x2013;spinal cord barrier suggests induced pharmacoresistance in ALS. Neurobiol. Dis. 2012;47:194&#x2013;200. doi: 10.1016/j.nbd.2012.03.040.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2012.03.040</ArticleId><ArticleId IdType="pmc">PMC3367047</ArticleId><ArticleId IdType="pubmed">22521463</ArticleId></ArticleIdList></Reference><Reference><Citation>Qosa H., Lichter J., Sarlo M., Markandaiah S.S., McAvoy K., Richard J.-P., Jablonski M.R., Maragakis N.J., Pasinelli P., Trotti D. Astrocytes drive upregulation of the multidrug resistance transporter ABCB1 (P-Glycoprotein) in endothelial cells of the blood-brain barrier in mutant superoxide dismutase 1-linked amyotrophic lateral sclerosis. Glia. 2016;64:1298&#x2013;1313. doi: 10.1002/glia.23003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/glia.23003</ArticleId><ArticleId IdType="pmc">PMC5541958</ArticleId><ArticleId IdType="pubmed">27158936</ArticleId></ArticleIdList></Reference><Reference><Citation>Milane A., Fernandez C., Vautier S., Bensimon G., Meininger V., Farinotti R. Minocycline and riluzole brain disposition: Interactions with p-glycoprotein at the blood?brain barrier. J. Neurochem. 2007;103:164&#x2013;173. doi: 10.1111/j.1471-4159.2007.04772.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2007.04772.x</ArticleId><ArticleId IdType="pubmed">17635670</ArticleId></ArticleIdList></Reference><Reference><Citation>Kia A., McAvoy K., Krishnamurthy K., Trotti D., Pasinelli P. Astrocytes expressing ALS-linked mutant FUS induce motor neuron death through release of tumor necrosis factor-alpha. Glia. 2018;66:1016&#x2013;1033. doi: 10.1002/glia.23298.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/glia.23298</ArticleId><ArticleId IdType="pmc">PMC5873384</ArticleId><ArticleId IdType="pubmed">29380416</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Dyke J.M., Smit-Oistad I.M., Macrander C., Krakora D., Meyer M.G., Suzuki M. Macrophage-mediated inflammation and glial response in the skeletal muscle of a rat model of familial amyotrophic lateral sclerosis (ALS) Exp. Neurol. 2016;277:275&#x2013;282. doi: 10.1016/j.expneurol.2016.01.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2016.01.008</ArticleId><ArticleId IdType="pmc">PMC4762214</ArticleId><ArticleId IdType="pubmed">26775178</ArticleId></ArticleIdList></Reference><Reference><Citation>Garc&#xed;a-Mart&#xed;nez C., Agell N., Llovera M., L&#xf3;pez-Soriano F.J., Argil&#xe9;s J.M. Tumour necrosis factor-&#x3b1; increases the ubiquitinization of rat skeletal muscle proteins. FEBS Lett. 1993;323:211&#x2013;214. doi: 10.1016/0014-5793(93)81341-V.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0014-5793(93)81341-V</ArticleId><ArticleId IdType="pubmed">8388807</ArticleId></ArticleIdList></Reference><Reference><Citation>Stommel E.W., Cohen J.A., Fadul C.E., Cogbill C.H., Graber D.J., Kingman L., Mackenzie T., Channon Smith J.Y., Harris B.T. Efficacy of thalidomide for the treatment of amyotrophic lateral sclerosis: A phase II open label clinical trial. Amyotroph. Lateral. Scler. 2009;10:393&#x2013;404. doi: 10.3109/17482960802709416.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482960802709416</ArticleId><ArticleId IdType="pmc">PMC3820489</ArticleId><ArticleId IdType="pubmed">19922130</ArticleId></ArticleIdList></Reference><Reference><Citation>Gowing G., Dequen F., Soucy G., Julien J.-P. Absence of Tumor Necrosis Factor- Does Not Affect Motor Neuron Disease Caused by Superoxide Dismutase 1 Mutations. J. Neurosci. 2006;26:11397&#x2013;11402. doi: 10.1523/JNEUROSCI.0602-06.2006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.0602-06.2006</ArticleId><ArticleId IdType="pmc">PMC6674545</ArticleId><ArticleId IdType="pubmed">17079668</ArticleId></ArticleIdList></Reference><Reference><Citation>Tortarolo M., Vallarola A., Lidonnici D., Battaglia E., Gensano F., Spaltro G., Fiordaliso F., Corbelli A., Garetto S., Martini E., et al. Lack of TNF-alpha receptor type 2 protects motor neurons in a cellular model of amyotrophic lateral sclerosis and in mutant SOD1 mice but does not affect disease progression. J. Neurochem. 2015;135:109&#x2013;124. doi: 10.1111/jnc.13154.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jnc.13154</ArticleId><ArticleId IdType="pubmed">25940956</ArticleId></ArticleIdList></Reference><Reference><Citation>Martorana F., Brambilla L., Valori C.F., Bergamaschi C., Roncoroni C., Aronica E., Volterra A., Bezzi P., Rossi D. The BH4 domain of Bcl-X(L) rescues astrocyte degeneration in amyotrophic lateral sclerosis by modulating intracellular calcium signals. Hum. Mol. Genet. 2012;21:826&#x2013;840. doi: 10.1093/hmg/ddr513.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddr513</ArticleId><ArticleId IdType="pubmed">22072391</ArticleId></ArticleIdList></Reference><Reference><Citation>Brambilla R., Ashbaugh J.J., Magliozzi R., Dellarole A., Karmally S., Szymkowski D.E., Bethea J.R. Inhibition of soluble tumour necrosis factor is therapeutic in experimental autoimmune encephalomyelitis and promotes axon preservation and remyelination. Brain. 2011;134:2736&#x2013;2754. doi: 10.1093/brain/awr199.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awr199</ArticleId><ArticleId IdType="pmc">PMC3170538</ArticleId><ArticleId IdType="pubmed">21908877</ArticleId></ArticleIdList></Reference><Reference><Citation>Petitpain N., Devos D., Bagheri H., Rocher F., Gouraud A., Masmoudi K., Coquerel A. Is TNF inhibitor exposure a risk factor for amyotrophic lateral sclerosis? Fundam. Clin. Pharmacol. 2019;33:689&#x2013;694. doi: 10.1111/fcp.12480.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/fcp.12480</ArticleId><ArticleId IdType="pubmed">31058354</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>